Introduction :-
Diabetes mellitus (DM) comprises a group of common metabolic disorders that share phenotype of hyperglycemia, and is often accompanied by presence of glucose in urine, from which the name of condition is derived (Gowenlock ,2002). It is found that a 14 to 16% decrease in macro vascular complication occurs forevery 1% absolute reductions in glycated Hb (Stratton et al ., 2000). However, HbA1c is not used for diagnosis as it is not sufficiently sensitive (Haslett et al., 2002). The measurement of glycated albumin (GA), which is considered to be a marker of glycemic control over the preceding 2–3 weeks, is convenient and accurate regardless of diet (Kouzuma et al., 2004). A recent study showed that GAcould be a better marker for glycemic control than HbA1c in diabetic patients, especially for evaluating glycemic excursion (Yoshiuchi et al., 2008).
The aim :-
It was to evaluate the relative contribution of fasting and postprandial plasma glucose to both glycated heamoglobin (HbA1C) and glycated albumin(GA) in type 2 diabetic patients.
Subjects and methods:-
This cross-sectional study was conducted on 50 non acarbose non insulin receiving type 2 diabetic subjects attending the out patient endocrinology clinc at Benha University Hospitals during the period from July 2014 to July 2015 after approval of BenhaUniversity ethical committee. All the patients were subjected to full history taking with special stress on age,sex,type and duration of diabetes ,medications and complications, Complete physical examination ,fasting , postprandial and prelaunch blood glucose measurement ,serum GA and HbA1C measurement. Serum GA concentration was quantitatively measured using an Enzyme–Linked Immuno-Sorbant Assay (ELISA) kit (Quantikinehuman GA Immunoassay; R&D Systems, Minneapolis, MN, USA) according to manufacturers’ instructions. Patients were classified into 3 groups according to HbA1C:Group 1 patients where HbA1C> 7.3% and it comprises 20 patients ,Group 2 patients where HbA1C ranges from 7.3% to 8.0% and it comprises10 patients and Group3 patientswhere HbA1C |
